Page last updated: 2024-09-04

naproxen and 3,5-di-tert-butyl-4-hydroxybenzoic acid

naproxen has been researched along with 3,5-di-tert-butyl-4-hydroxybenzoic acid in 2 studies

Compound Research Comparison

Studies (naproxen)	Trials (naproxen)	Recent Studies (post-2010) (naproxen)	Studies (3,5-di-tert-butyl-4-hydroxybenzoic acid)	Trials (3,5-di-tert-butyl-4-hydroxybenzoic acid)	Recent Studies (post-2010) (3,5-di-tert-butyl-4-hydroxybenzoic acid)
4,551	1,057	1,429	15	0	7

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, J; Dobson, RL; Eichhold, TH; Enzweiler, K; Gan, L; Green, SA; Janusz, JM; Kellstein, DE; Kuhlenbeck, DL; Magrisso, IJ; Ridgeway, JM; Rosario-Jansen, T; Scherz, MW; Tulich, JL; Wehmeyer, KR; Wu, LI; Young, PA	1
Kourounakis, AP; Ladopoulou, E; Matralis, AN	1

Other Studies

2 other study(ies) available for naproxen and 3,5-di-tert-butyl-4-hydroxybenzoic acid

Article	Year
New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position. Journal of medicinal chemistry, 1998, Aug-27, Volume: 41, Issue:18 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Enzyme Inhibitors; Humans; Isoenzymes; Lipoxygenase Inhibitors; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship	1998
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action. Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8 Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats	2013

Article

Year

New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position.

Journal of medicinal chemistry, 1998, Aug-27, Volume: 41, Issue:18

Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzofurans; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Enzyme Inhibitors; Humans; Isoenzymes; Lipoxygenase Inhibitors; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship

1998

New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.

Journal of medicinal chemistry, 2013, Apr-25, Volume: 56, Issue:8

Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats

2013